SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-017981
Filing Date
2023-11-07
Accepted
2023-11-07 16:02:38
Documents
66
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20230930x10q.htm   iXBRL 10-Q 1929957
2 EX-31.1 crvs-20230930xex31d1.htm EX-31.1 11899
3 EX-31.2 crvs-20230930xex31d2.htm EX-31.2 11837
4 EX-32.1 crvs-20230930xex32d1.htm EX-32.1 11818
  Complete submission text file 0001558370-23-017981.txt   6902257

Data Files

Seq Description Document Type Size
5 EX-101.SCH crvs-20230930.xsd EX-101.SCH 41771
6 EX-101.CAL crvs-20230930_cal.xml EX-101.CAL 48575
7 EX-101.DEF crvs-20230930_def.xml EX-101.DEF 152350
8 EX-101.LAB crvs-20230930_lab.xml EX-101.LAB 368470
9 EX-101.PRE crvs-20230930_pre.xml EX-101.PRE 277109
60 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20230930x10q_htm.xml XML 1158150
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 231383574
SIC: 2834 Pharmaceutical Preparations